Developing a predictive signature for two trial endpoints using the cross-validated risk scores method.

@article{Cherlin2021DevelopingAP,
  title={Developing a predictive signature for two trial endpoints using the cross-validated risk scores method.},
  author={Svetlana Cherlin and James M. S. Wason},
  journal={Biostatistics},
  year={2021}
}
The existing cross-validated risk scores (CVRS) design has been proposed for developing and testing the efficacy of a treatment in a high-efficacy patient group (the sensitive group) using high-dimensional data (such as genetic data). The design is based on computing a risk score for each patient and dividing them into clusters using a nonparametric clustering procedure. In some settings, it is desirable to consider the tradeoff between two outcomes, such as efficacy and toxicity, or cost and… 
2 Citations

Figures and Tables from this paper

Cross-validated risk scores adaptive enrichment (CADEN) design
TLDR
It is shown that when there exists a sensitive group of patients, CADEN achieves a higher power and a reduction in the expected sample size, in comparison to the CVRS design, and is implemented in an R package caden.
Innovative trial approaches in immune-mediated inflammatory diseases: current use and future potential
TLDR
Application of innovative statistical methodology to IMID trials has the potential to greatly improve efficiency, to generalise and extrapolate trial results, and to further personalise treatment strategies.

References

SHOWING 1-10 OF 56 REFERENCES
Developing and testing high-efficacy patient subgroups within a clinical trial using risk scores
TLDR
A variation to the ASD method, the cross-validated risk scores (CVRS) design method, that does not require selection of any tuning parameters is proposed and has a substantial reduction in the computational time required.
Exploratory identification of predictive biomarkers in randomized trials with normal endpoints
One of the main endeavours in present‐day medicine, especially in oncological research, is to provide evidence for individual treatment decisions (“stratified medicine”). In the pursuit of optimal
Subgroup selection in adaptive signature designs of confirmatory clinical trials
TLDR
A simple and general characterization of the optimal subgroup that maximizes the power for demonstrating treatment efficacy or the expected gain based on a specified utility function is provided and a procedure for subgroup selection that involves prediction modelling, augmented inverse probability weighting and low dimensional maximization is proposed.
Subgroup identification from randomized clinical trial data
TLDR
This work considers the problem of identifying a subgroup of patients who may have an enhanced treatment effect in a randomized clinical trial, and it is desirable that the subgroup be defined by a limited number of covariates, and presents a method developed to find subgroups ofEnhanced treatment effect.
A regression tree approach to identifying subgroups with differential treatment effects
TLDR
Three new regression tree algorithms are introduced that are practically free of selection bias and are applicable to data from randomized trials with two or more treatments, censored response variables, and missing values in the predictor variables.
Effectively Selecting a Target Population for a Future Comparative Study
TLDR
This article shows a systematic, effective way to identify a promising population, for which the new treatment is expected to have a desired benefit, using the data from a current study involving similar comparator treatments, and proposes the best scoring system among all competing models.
Developing and Validating Continuous Genomic Signatures in Randomized Clinical Trials for Predictive Medicine
TLDR
Cross-validated patient-level survival curves were developed to predict survival distributions of individual future patients as a function of whether or not they are treated with thalidomide and with regard to their baseline prognostic and predictive signature indices.
Designing precision medicine trials to yield a greater population impact
TLDR
A new targeted clinical trial design is proposed, termed as Max‐Impact design, which selects the appropriate subpopulation for a clinical trial and aims to optimize population impact once the trial is completed.
A Simple Method for Estimating Interactions Between a Treatment and a Large Number of Covariates
TLDR
It is shown that coupled with an efficiency augmentation procedure, this method produces clinically meaningful estimators in a variety of settings and can be useful for practicing personalized medicine: determining from a large set of biomarkers, the subset of patients that can potentially benefit from a treatment.
The Cross-Validated Adaptive Signature Design
TLDR
A cross-validation extension of the adaptive signature design is proposed that optimizes the efficiency of both the classifier development and the validation components of the design, and is applied to data from a randomized breast cancer trial.
...
...